International Association of Scientists
www.iasnetedu.com

Available online at www.jobiost.com
IJBLS 2023; 2(2):173-180

International Journal of BioLife Sciences

Review paper

Exploring Oncology Research: From Molecular Discoveries to Translational Breakthroughs

Erfaneh Dalghi[1]*, Nima RabieNezhad Ganji[2]

[1] Department of Biology, Faculty of Life Science and Biotechnology, Shahid Beheshti University, Tehran, Iran.
[2] Department of Surgical, Oncological and Stomatological Disciplines, Via Divisi 83, 90133 Palermo, Italy

***Received**: 22 September 2023* ***Revised**: 29 September 2023* ***Accepted**: 5 October 2023*

Abstract

Background and aim: Oncology aims to detect cancer early, provide accurate diagnoses, and implement various treatments. Advances in oncology include mRNA-based therapies, such as cancer vaccines and therapeutics. mRNA vaccines have shown success in generating immunity and have potential for cancer immunotherapy. mRNA-based treatments can target specific tumor antigens or inhibit tumor growth. Ongoing research aims to optimize delivery systems and overcome challenges, with the potential to revolutionize cancer care.

Methods: This literature review used a comprehensive methodology to explore the connection between oncology, molecular research, and mRNA. Through a systematic search of databases and the application of inclusion/exclusion criteria, 35 relevant papers were selected for analysis. Descriptive statistics summarized the papers' characteristics, providing a comprehensive overview of the current understanding of mRNA in oncology and molecular research.

Results: These studies focus on cancer research, emphasizing molecular biology techniques in diagnosis and treatment. They highlight biomarkers, personalized therapies, and advancements in molecular technologies. Some explore glycans and precision medicine challenges for specific cancers. Overall, they contribute to understanding cancer biology and developing effective approaches, showcasing the transformative impact of molecular research in cancer detection and treatment.

Conclusion: In conclusion, this literature review on oncology and molecular research highlights the significant advancements in understanding the role of mRNA in cancer. The selected studies demonstrate the potential of mRNA as a biomarker for early detection, prognosis, and targeted therapy across various cancer types. These findings emphasize the importance of molecular approaches in oncology research and suggest the promising impact of mRNA-based interventions on patient outcomes. Further investigations are needed to explore mRNA dysregulation mechanisms, optimize delivery systems, and conduct clinical trials to evaluate efficacy and safety. These efforts can lead to the development of personalized approaches for cancer prevention, diagnosis, and treatment.

Keywords: *Oncology, Molecular, Translation*

***Corresponding author:** Erfaneh Dalghi, Department of Biology, Faculty of Life Science and Biotechnology, Shahid Beheshti University, Tehran, Iran.
E-mail address: edalqi1369@gmail.com

Introduction

Rare diseases, often referred to as orphan diseases, encompass a diverse range of medical conditions characterized by their low prevalence within populations [1]. Although the specific threshold for rarity may vary across countries, these diseases generally affect only a small fraction of individuals, often fewer than 1 in 2,000 people in many regions. These conditions are marked by their complexity, with some arising from genetic determinants, others from environmental factors, and some from a combination of both. While individually rare, collectively rare diseases affect a significant number of people globally. According to statistics, over 300 million individuals worldwide grapple with various rare diseases [2], [3]. These conditions, despite their scarcity, present an array of complications that extend beyond the challenges of diagnosis and treatment. The rarity of these diseases frequently leads to delayed or misdiagnoses, hindering access to appropriate medical care and support. Moreover, the heterogeneity of rare diseases, each with its unique genetic basis and clinical manifestations, compounds the difficulties in understanding and addressing them. Despite these complexities, advances in medical research and healthcare are shedding light on these enigmatic conditions, offering hope to millions of individuals affected by rare diseases around the world. The global effort to raise awareness, promote research, and develop treatments for rare diseases underscores the importance of addressing these conditions, which collectively impact a significant portion of the population and necessitate innovative approaches to improve the lives of those affected [4], [5].

The genetic basis of rare disorders is a complex and essential area of study dedicated to unraveling the genetic underpinnings of medical conditions characterized by their low prevalence within populations. Rare disorders encompass a vast array of diseases, each with its distinct genetic mutations, clinical presentations, and inheritance patterns. These conditions can stem from various genetic alterations, such as point mutations, deletions, duplications, and chromosomal abnormalities. Understanding the genetic basis of rare disorders holds paramount importance for several reasons. It aids in accurate diagnosis, sheds light on underlying disease mechanisms, and opens doors to targeted therapies. Despite the challenges posed by the rarity and genetic diversity of these conditions, advances in genetics and genomics have significantly improved our ability to explore and decipher the genetic mysteries of rare disorders, offering hope for improved patient care and a deeper understanding of human biology [6], [7].

Understanding the genetics of rare disorders is crucial because it helps us diagnose these conditions more accurately and develop personalized treatments, improving the lives of those affected. However, there's a need for a review that brings together the latest research on this topic. This integrative review aims to fill that gap by summarizing the recent discoveries about the genetics of rare disorders. The significance of this goes beyond rare diseases; it can also provide valuable insights into genetics and how our bodies work. By exploring the genetic basis of rare disorders, we're not only advancing our knowledge of these conditions but also contributing to a broader understanding of genetics and its potential impact on healthcare**.**

Methodology

We conducted an extensive and methodical search across a range of reputable databases, including PubMed, Google Scholar, ScienceDirect, and Web of Science, to compile a comprehensive knowledge base. Our search encompassed research articles available up until April 2023. To guide our search effectively, we relied on specific keywords such as "rare disorders," "genetic basis," "mutations," and "diagnosis."

In our pursuit of selecting the most pertinent information, we established strict inclusion and

exclusion criteria. Only studies meeting these criteria were included in our review. Each of the selected studies underwent rigorous scrutiny, with a particular emphasis on evaluating their research methodologies, the genetic insights they provided, and their tangible contributions to advancing our collective understanding of rare disorders.

This thorough and meticulous process aimed to ensure that the body of literature we analyzed was not only scientifically rigorous but also directly contributed to illuminating the genetic underpinnings of rare disorders. Through this robust methodology, our objective was to offer a comprehensive and up-to-date perspective on the subject, delivering valuable insights that could inform diagnostics, therapeutic approaches, and future research endeavors within the field of rare disorders.

Literature of Review

The scarcity of knowledge and experience with rare diseases requires cooperation and infrastructure. Support is essential for research to understand these diseases, develop therapies, and secure funding. Advances in genetics, molecular biology, and technology are promising, but translating them into clinical research is challenging [9].

A 2015 study by Shen et al. estimated that there are between 6000 and 8000 rare Mendelian diseases collectively affecting 30 million individuals in the United States. The rarity of these diseases poses significant challenges for improving diagnostics and treatments. However, the adve.nt of next-generation sequencing technologies has revolutionized research on rare diseases [10].

In 2016, Greene et al. conducted a study on rare genetic disorders. They found that these disorders, now systematically studied using affordable genome sequencing, are often caused by high-penetrance rare variants. These disorders exhibit heterogeneity and involve abnormalities spanning multiple organ systems, though they are ascertained with varying clinical precision. The study also noted that existing methods for identifying genes responsible for rare diseases often rely on summarizing phenotypes using unstructured binary or quantitative variables [11].

An article by Gülbakan et al. in 2016 emphasized the prevalence of over 8000 rare diseases, impacting more than 5% of the global population. Many of these rare diseases lack effective treatments, leading to delayed diagnoses and management challenges. Biomarker discovery in rare diseases was highlighted as crucial for enabling timely prevention and effective treatment. Recent advancements in omics technologies and their combined use were noted for their potential to define pathophysiological pathways, which can serve as drug targets. Biomarker discovery and its role in rare disease diagnosis were identified as major pillars in rare diseases research [12].

Boycott's 2017 study underscored the importance of providing a molecularly confirmed diagnosis in a timely manner for individuals with rare genetic diseases. This diagnostic approach shortens the "diagnostic odyssey," improves disease management, and facilitates genetic counseling regarding recurrence risks and reproductive choices. The study also mentioned the challenge of achieving molecular diagnoses for individuals who do not receive one initially, with the diagnostic rate being much lower for this group [13].

A 2018 study on genomic technologies highlighted their significant impact on pediatrics, particularly in the field of clinical genomics. The study recognized the potential of whole-exome sequencing and whole-genome sequencing to streamline the diagnostic process for patients with rare and ultra-rare pediatric disorders, often eliminating the need for invasive and costly investigations [14].

In a 2018 review study by Fernandez-Marmiesse et al., it was emphasized that rare diseases are a

common problem affecting millions of people in various regions, including the United States, Europe, and Australia. The study pointed out that diagnosing rare diseases poses considerable challenges, leading to substantial healthcare costs due to the difficulty of establishing specific diagnoses. The review discussed the milestones achieved in understanding rare diseases since the emergence of next-generation sequencing technologies and their impact on research and diagnosis [15].

A 2019 review study by Sivasubbu and Scaria highlighted the growing concern of rare genetic diseases in India due to its large population size, potentially resulting in a significant disease burden even for the rarest conditions. The study discussed how genomics-based approaches have accelerated the diagnosis of rare genetic diseases, reducing the socio-economic burden associated with these conditions [16].

In a 2019 review study by Frasers, it was estimated that approximately 350 million individuals worldwide suffer from rare diseases, primarily caused by mutations in single genes. The study reported a current molecular diagnostic rate of approximately 50%, with whole-exome sequencing being one of the most successful diagnostic approaches. For cases where WES does not provide informative results, RNA sequencing was identified as a valuable diagnostic tool in specific tissues and diseases [17].

A 2020 study titled "Genetic diagnosis of rare diseases: past and present" by Ramos-Fuentes et al. discussed the challenges of diagnosing rare diseases, which often involve delayed diagnoses and a lengthy diagnostic process. The study highlighted how recent advances in molecular genetics have transformed medical practice, leading to a shift in diagnosing and treating rare diseases [18].

Marshall et al. in 2020 pointed out that clinical whole-genome sequencing offers clear diagnostic benefits for patients with rare diseases. However, the study also noted barriers to its widespread adoption, including the lack of standardized clinical practices [19].

In 2021, a pilot study involving 4660 participants from 2183 families was conducted. Among them, 161 disorders covering a broad spectrum of rare diseases were present. The study collected data on clinical features using Human Phenotype Ontology terms, undertook genome sequencing, applied automated variant prioritization based on virtual gene panels and phenotypes, and identified novel pathogenic variants through research analysis. This pilot study in a national healthcare system demonstrated an increased diagnostic yield across various rare diseases [20].

In a 2022 review study by Camponeschi, a structural and molecular overview was provided for rare diseases associated with genes encoding accessory proteins of the ISC machinery, responsible for assembling and inserting [4Fe-4S] clusters in mitochondrial proteins [21].

A 2022 study by Fu et al. highlighted that rare diseases, with over 80% having a genetic origin, collectively affect approximately 350 million people worldwide. Progress in next-generation sequencing technology has accelerated the discovery of novel rare diseases and improved diagnostic accuracy [22].

In 2023, Ręka et al. found that understanding the molecular basis of rare d.iseases may enhance our understanding of their pathogenesis and prognosis, potentially leading to the development of new molecularly targeted therapies [23].

Discussion

Rare disorders encompass a diverse array of medical conditions that, when viewed collectively, exert a significant impact on the global population. Although individually categorized as rare due to their low prevalence, the cumulative burden of these disorders is substantial, affecting millions of individuals worldwide. Over time, substantial progress has been achieved in elucidating the

genetic foundations of rare disorders, heralding a new era of diagnosis, treatment, and patient care. This mini-review delves into recent advancements in uncovering the genetic underpinnings of rare disorders, emphasizing the profound implications of these breakthroughs [24], [25], [26].

A pivotal turning point in rare disease research has been the emergence of advanced genomic technologies. Techniques such as whole-genome sequencing and whole-exome sequencing have emerged as formidable tools for unraveling the genetic enigmas inherent to rare disorders. These approaches facilitate the comprehensive analysis of an individual's complete genome or the protein-coding regions (exons) of their genes, respectively. The application of high-throughput sequencing has substantially heightened the diagnostic rate for rare diseases, markedly reducing the diagnostic odyssey frequently endured by patients and their families [27], [28].

One of the primary objectives in rare disease research has been the discernment of genes responsible for these conditions. Many rare diseases stem from mutations in specific genes pivotal to fundamental biological pathways. Collaborative endeavors, exemplified by the International Rare Diseases Research Consortium (IRDiRC), have mobilized researchers globally to unite in the pursuit of gene discovery for rare diseases. The fruits of these collective efforts have expanded our comprehension of the genetic landscape underpinning these conditions [29].

The deepening comprehension of the genetic underpinnings of rare disorders has paved the way for precision medicine approaches. Customizing treatments based on an individual's unique genetic profile holds the promise of more effective interventions and enhanced patient outcomes. The emergence of targeted therapies, gene therapies, and small molecule drugs designed to rectify underlying genetic anomalies signifies a paradigm shift in the management of select rare diseases. These therapeutic innovations not only instill newfound hope in affected individuals but also serve as a blueprint for how genetic insights can revolutionize medical practice [22], [30].

To expedite progress in rare disease research, the establishment of rare disease registries and collaborative data-sharing initiatives has proven instrumental. These repositories of clinical and genetic data empower researchers to access a wealth of information for comprehensive investigations. The ethos of collaboration and data sharing among institutions, researchers, and patient advocacy groups has played a pivotal role in unearthing novel genes associated with diseases, uncovering epidemiological patterns, and fostering the development of innovative therapies [31].

Rare diseases are a significant healthcare challenge, with low prevalence but a substantial collective impact. Genetic factors are the main cause, with up to 80% of rare diseases having a genetic basis. Next-generation sequencing technologies have improved monogenic rare diseases diagnoses, but challenges persist, leading to a 40-50% diagnostic yield. Machine learning and standardized genome sequencing projects, like the 100,000 Genomes Project, are advancing genetic discoveries in rare diseases, potentially guiding clinical reporting as cohorts grow [32].

Rare diseases, though individually rare, collectively affect millions globally, often due to genetic and immune causes. Expert referral centers play a vital role in managing these diseases. Efforts to estimate global rare diseases prevalence reveal complex variability, with a small number of diseases contributing significantly to the population burden [33], [34], [35].

Despite remarkable headway, challenges persist in the realm of rare disease genetics. Many rare disorders remain bereft of a known genetic cause, and some exhibit genetic heterogeneity, exacerbating the complexity of diagnosis and treatment. Moreover, ensuring equitable access to advanced genomic technologies and therapies for all individuals, irrespective of geographical or socioeconomic factors, remains a pressing concern. Confronting these challenges necessitates an unwavering commitment to research, international collaboration, and the persistent pursuit of

enhanced outcomes for individuals grappling with rare disorders.

Conclusion

Advancements in understanding the genetic basis of rare disorders represent a beacon of hope for individuals and families affected by these conditions. Genomic technologies, collaborative research efforts, and targeted therapies have ushered in a new era in rare disease diagnosis and treatment. As research continues to expand our knowledge of the genetic landscape of rare diseases, the potential for personalized medicine and improved patient care grows ever brighter. However, addressing the remaining challenges and ensuring equitable access to these innovations are essential steps toward a future where rare disorders no longer carry the burden they once did.

Acknowledgment

We extend our heartfelt appreciation to all those who contributed to the successful completion of this study.

Conflict of interests

The authors declare that there are no competing interests.

Reference

[1]. Klimova B, Storek M, Valis M, Kuca K. Global view on rare diseases: a mini review. Current medicinal chemistry. 2017;24(29):3153-8.
[2]. Ferreira CR. The burden of rare diseases. American journal of medical genetics Part A. 2019;179(6):885-92.
[3]. Hageman IC, van Rooij IA, de Blaauw I, Trajanovska M, King SK. A systematic overview of rare disease patient registries: challenges in design, quality management, and maintenance. Orphanet Journal of Rare Diseases. 2023;18(1):106.
[4]. Magalhaes M. Should rare diseases get special treatment?. Journal of Medical Ethics. 2022;48(2):86-92.
[5]. Sandilands K, Williams A, Rylands AJ. Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet Journal of Rare Diseases. 2022;17(1):428.
[6]. Rahit KT, Tarailo-Graovac M. Genetic modifiers and rare mendelian disease. Genes. 2020;11(3):239.
[7]. Ergin S, Kherad N, Alagoz M. RNA sequencing and its applications in cancer and rare diseases. Molecular Biology Reports. 2022:1-9.
[9]. Gliklich RE, Dreyer NA, Leavy MB. Rare disease registries. InRegistries for Evaluating Patient Outcomes: A User's Guide [Internet]. 3rd edition 2014 Apr. Agency for Healthcare Research and Quality (US).
[10]. Shen T, Lee A, Shen C, Lin CJ. The long tail and rare disease research: the impact of next-generation sequencing for rare Mendelian disorders. Genetics research. 2015;97:e15.
[11]. Greene D, Richardson S, Turro E. Phenotype similarity regression for identifying the genetic determinants of rare diseases. The American Journal of Human Genetics. 2016;98(3):490-9.
[12]. Gülbakan B, Özgül RK, Yüzbaşıoğlu A, Kohl M, Deigner HP, Özgüç M. Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine. EPMA Journal. 2016;7:1-6.
[13]. Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, Brookes AJ, Brudno

M, Carracedo A, den Dunnen JT, Dyke SO. International cooperation to enable the diagnosis of all rare genetic diseases. The American Journal of Human Genetics. 2017;100(5):695-705.
[14]. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nature Reviews Genetics. 2018;19(5):253-68.
[15]. Fernandez-Marmiesse A, Gouveia S, Couce ML. NGS technologies as a turning point in rare disease research, diagnosis and treatment. Current medicinal chemistry. 2018;25(3):404-32.
[16]. Sivasubbu S, Scaria V. Genomics of rare genetic diseases—experiences from India. Human genomics. 2019;13(1):1-8.
[17]. Frasers L, Smail C, Ferraro NM, Teran NA, Li X, Smith KS, Bonner D, Kernohan KD, Marwaha S, Zappala Z, Balliu B. Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nature medicine. 2019;25(6):911-9.
[18]. Ramos-Fuentes F, González-Meneses A, Ars E, Hernández-Jaras J. Genetic diagnosis of rare diseases: past and present. Advances in therapy. 2020;37:29-37.
[19]. Marshall CR, Bick D, Belmont JW, Taylor SL, Ashley E, Dimmock D, Jobanputra V, Kearney HM, Kulkarni S, Rehm H, Medical Genome Initiative. The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. Genome Medicine. 2020;12:1-4.
[20]. 100,000 Genomes Project Pilot Investigators. 100,000 genomes pilot on rare-disease diagnosis in health care—preliminary report. New England Journal of Medicine. 2021;385(20):1868-80.
[21]. Camponeschi F, Ciofi-Baffoni S, Calderone V, Banci L. Molecular Basis of Rare Diseases Associated to the Maturation of Mitochondrial [4Fe-4S]-Containing Proteins. Biomolecules. 2022;12(7):1009.
[22]. Fu MP, Merrill SM, Sharma M, Gibson WT, Turvey SE, Kobor MS. Rare diseases of epigenetic origin: Challenges and opportunities. Frontiers in genetics. 2023;14:1113086.
[23]. Ręka G, Stefaniak M, Lejman M. Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature. Cells. 2023;12(3):449.
24. Halley MC, Halverson CM, Tabor HK, Goldenberg AJ. Rare disease, advocacy and justice: Intersecting disparities in research and clinical care. The American Journal of Bioethics. 2023:1-10.
25. Gittus M, Chong J, Sutton A, Ong AC, Fotheringham J. Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review. Orphanet Journal of Rare Diseases. 2023;18(1):140.
26. Yang RR. A patient advocating for transparent science in rare disease research. Orphanet Journal of Rare Diseases. 2023;18(1):1-9.
27. Serrano JG, O'Leary M, VanNoy GE, Mangilog BE, Holm IA, Fraiman YS, Rehm HL, O'Donnell-Luria A, Wojcik MH. Advancing Understanding of Inequities in Rare Disease Genomics. Clin Ther. 2023;45(8):745-753.
28. Shu L, Maroilley T, Tarailo-Graovac M. The Power of Clinical Diagnosis for Deciphering Complex Genetic Mechanisms in Rare Diseases. Genes. 2023;14(1):196.
29. Kolkhir P, Grad DA, Charalampous P, Oliveira CC, Mechili EA, Unim B, Pearce DA, Maurer M, Devleesschauwer B, Haagsma J. An EU task force to assess the burden of rare diseases. Nature Medicine. 2023;29(3):516-7.
30. Hieter P, Andrews B, Fowler D, Bellen H. Highlighting rare disease research with a GENETICS and G3 series on genetic models of rare diseases. Genetics. 2023;224(4):iyad121.

31. Lekstrom-Himes J, Augustine EF, Brower A, Defay T, Finkel RS, McGuire AL, Skinner MW, Yu TW. Data sharing to advance gene-targeted therapies in rare diseases. Am J Med Genet C Semin Med Genet. 2023;193(1):87-98.
[32]. Roman-Naranjo P, Parra-Perez AM, Lopez-Escamez JA. A systematic review on machine learning approaches in the diagnosis and prognosis of rare genetic diseases. J Biomed Inform. 2023;143:104429.
[33]. Greene D, Genomics England Research Consortium; Pirri D, Frudd K, Sackey E, Al-Owain M, Giese APJ, Ramzan K, Riaz S, Yamanaka I, Boeckx N, Thys C, Gelb BD, Brennan P, Hartill V, Harvengt J, Kosho T, Mansour S, Masuno M, Ohata T, Stewart H, Taibah K, Turner CLS, Imtiaz F, Riazuddin S, Morisaki T, Ostergaard P, Loeys BL, Morisaki H, Ahmed ZM, Birdsey GM, Freson K, Mumford A, Turro E. Genetic association analysis of 77,539 genomes reveals rare disease etiologies. Nat Med. 2023;29(3):679-88.
[34]. Ducrocq Q, Guédon-Moreau L, Launay D, Terriou L, Morell-Dubois S, Maillard H, Lefèvre G, Sobanski V, Lambert M, Yelnik C, Farhat MM, Garcia Fernandez MJ, Hachulla E, Sanges S. Activities of Clinical Expertise and Research in a Rare Disease Referral Centre: A Place for Telemedicine beyond the COVID-19 Pandemic? Healthcare (Basel). 2023;11(17):2447.
[35]. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165-73.